Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules

Neurology

Volumn 57, Issue 4, 2001, Pages 582-589

  Wilder, B J ^a,d   Leppik, I ^b   Hietpas, T J ^b   Cloyd, J C ^e   Randinitis, E J ^e   Cook, J ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIET; DISEASE CONTROL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; FEMALE; FOOD; HUMAN; LIPID DIET; MALE; PRIORITY JOURNAL; SEIZURE; STEADY STATE;

EID: 0035964221     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.4.582     Document Type: Article

References (43)

1. Scott-Levin Physician Drug and Diagnosis Audit
2. Laboratory monitoring of antiepileptic drugs
3. Generic substitutions for antiepileptic drugs
4. Effect of antacids on phenytoin bioavailability
5. Reduced seizure control due to spoiled phenytoin capsules
6. Phenytoin
7. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food
8. Patterns and challenges of antiepileptic drug pharmacokinetics in the elderly
9. Bioavailability of phenytoin sodium capsules available in Thailand II: In vivo study
10. Bioavailability and dissolution of proprietary and generic formulations of phenytoin
11. Comparative bioavailability of several phenytoin preparations marketed in Austria
12. Bioavailability of 11 phenytoin products
13. Generic antiepileptic drugs in the elderly: A special consideration
14. Possible gender effect with phenytoin pharmaco-kinetics in epilepsy patients
15. Rapid and slow release of phenytoin in epileptic patients at a steady state: Comparative plasma levels and toxicity
16. Sensitivity analysis of the effect of phenytoin bioavailability or dosage form content on mean steady state phenytoin concentrations
17. Individualization of phenytoin dosage regimens
18. Phenytoin: Absorption, distribution, and excretion
19. Effect of a high-fat meal on the bioavailability of phenytoin in a commercial powder with a large particle size
20. Opposite effects of carbohydrate and protein on phenytoin absorption in man
21. Influence of food on the absorption of phenytoin in man
22. Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation
23. Serum phenytoin levels in the management of epilepsy
24. The effect of food on the absorption of phenytoin
25. Pharmacokinetic profile of a 300-mg extended phenytoin sodium capsule (Dilantin) formulation
26. Effects of phenytoin in patients with epilepsy in relation to its concentration in plasma
27. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: Individual variation in relation to seizure frequency and type
28. Comparison on bioequivalence of four phenytoin preparations in patients with multiple-dose treatment
29. Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients
30. Outbreak of anticonvulsant intoxication in an Australian city
31. Comparative bioavailability of a generic phenytoin and Dilantin
32. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy
33. Plasma level studies on different brands of sodium diphenylhydantoin (DPH) and primidone
34. Phenytoin I: In vitro-in vivo bioequivalence for standard 100-mg phenytoin sodium capsules
35. Phenytoin II. In-vitro-in-vivo bioequivalence for standard 100-mg phenytoin sodium capsules
36. Rapid and slow release of phenytoin in epileptic patients at a steady state. Assessment of relative bioavailability utilizing Michaelis-Menten parameters
37. F-D-C reports. Bolar recalls generic version of Dyazide and extended elease phenytoin saying "bioequivalence cannot be assured"; products represent 52% of sales."
38. F-D-C Reports. FDA recalls and court actions, extended sodium phenytoin capsules, USP, 100mg, Sidmark
39. Effect of food on the bioavailability of 100-mg Dilantin Kapseals
40. Phenytoin: Pharmacokinetics and bioavailability
41. Age and phenytoin kinetics in adult epileptics